Tirbanibulin
Sponsors
Almirall S.A., Almirall, S.A., Medical University of Graz, Centre Hospitalier Universitaire de Nice
Conditions
Actinic KeratosesActinic KeratosisActinic Keratosis on the Face or ScalpCell CarcinomaKeratosis, Actinic
Phase 2
Phase 3
A Phase 3, Multicentre, Randomised, Double-blind, Vehicle-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tirbanibulin 10 mg/g Ointment Applied to a Treatment Field Larger Than 25 cm2 and up to 100 cm2 in Adult Patients With Actinic Keratosis
CompletedCTIS2023-505487-11-00
Start: 2023-12-21End: 2025-11-25Target: 269Updated: 2025-12-10
A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis
CompletedNCT06135415
Start: 2023-12-21End: 2025-11-25Updated: 2026-03-25
Phase 4
Tirbanibulin 1% Ointment for the Treatment of Chronically Sun-damaged Skin on the Face
CompletedNCT05900258
Start: 2023-05-11End: 2023-11-13Updated: 2023-11-14
Tirbanibulin 1% Ointment for the Treatment of Actinic Keratosis on the Back of the Hands
WithdrawnNCT06026358
Start: 2023-10-31End: 2024-12-31Updated: 2024-05-30